|
2019-09-11 |
2019-09-10 |
PS
Planned sale
|
Hadar Ilan
CFO & Country Manager
|
34,392
-27.8%
3.50
USD 120,375
|
34,392
-27.8%
|
3.50
|
USD 120,375
|
|
|
2019-09-11 |
2019-09-09 |
PS
Planned sale
|
Hadar Ilan
CFO & Country Manager
|
9,420
-7.1%
3.50
USD 32,991
|
9,420
-7.1%
|
3.50
|
USD 32,991
|
|
|
2019-08-28 |
2019-08-26 |
S
Sale
|
KAZANCHYAN ANNA
Non-Executive Director
|
7,049
-15.8%
3.27
USD 23,050
|
7,049
-15.8%
|
3.27
|
USD 23,050
|
|
|
2019-07-17 |
2019-07-15 |
PS
Planned sale
|
KAZANCHYAN ANNA
|
808
-1.8%
2.31
USD 1,866
|
808
-1.8%
|
2.31
|
USD 1,866
|
|
|
2019-07-03 |
2019-07-01 |
S
Sale
|
Harsch Mutya
CLO and General Counsel
|
639
-1.2%
2.35
USD 1,502
|
639
-1.2%
|
2.35
|
USD 1,502
|
|
|
2019-07-03 |
2019-07-01 |
S
Sale
|
Stuart Iain
Chief Scientific Officer
|
951
-1.5%
2.35
USD 2,235
|
951
-1.5%
|
2.35
|
USD 2,235
|
|
|
2019-07-03 |
2019-07-01 |
S
Sale
|
Domzalski David
CEO
Executive Director
|
3,355
-1.6%
2.35
USD 7,884
|
3,355
-1.6%
|
2.35
|
USD 7,884
|
|
|
2019-05-20 |
2019-05-20 |
PS
Planned sale
|
KAZANCHYAN ANNA
Non-Executive Director
|
10,600
-18.9%
2.61
USD 27,666
|
10,600
-18.9%
|
2.61
|
USD 27,666
|
|
|
2019-04-03 |
2019-04-01 |
S
Sale
|
Stuart Iain
Chief Scientific Officer
|
1,696
-2.6%
3.75
USD 6,360
|
1,696
-2.6%
|
3.75
|
USD 6,360
|
|
|
2019-04-03 |
2019-04-01 |
S
Sale
|
Harsch Mutya
CLO and General Counsel
|
2,519
-4.6%
3.75
USD 9,446
|
2,519
-4.6%
|
3.75
|
USD 9,446
|
|
|
2019-04-03 |
2019-04-01 |
S
Sale
|
Domzalski David
CEO
Executive Director
|
5,096
-2.3%
3.75
USD 19,110
|
5,096
-2.3%
|
3.75
|
USD 19,110
|
|
|
2019-03-06 |
2019-03-05 |
B
Purchase
|
Wiley Matthew T.
Chief Commercial Officer
|
13,440
+26.9%
3.76
USD 50,534
|
13,440
+26.9%
|
3.76
|
USD 50,534
|
|
|
2018-12-06 |
2018-12-03 |
S
Sale
|
Domzalski David
CEO
Executive Director
|
68
-0.0%
4.05
USD 275
|
68
-0.0%
|
4.05
|
USD 275
|
|
|
2018-12-06 |
2018-11-28 |
B
Purchase
|
Schwartz Aharon
Non-Executive Director
|
12,200
+12.2%
3.88
USD 47,373
|
12,200
+12.2%
|
3.88
|
USD 47,373
|
|
|
2018-12-06 |
2018-11-27 |
B
Purchase
|
Schwartz Aharon
Non-Executive Director
|
50,000
+100.0%
3.92
USD 195,800
|
50,000
+100.0%
|
3.92
|
USD 195,800
|
|
|
2018-12-06 |
2018-11-26 |
B
Purchase
|
Schwartz Aharon
Non-Executive Director
|
50,000
+inf%
3.89
USD 194,600
|
50,000
+inf%
|
3.89
|
USD 194,600
|
|
|
2018-11-20 |
2018-11-19 |
S
Sale
|
Domzalski David
CEO
Executive Director
|
5,036
-3.3%
3.90
USD 19,640
|
5,036
-3.3%
|
3.90
|
USD 19,640
|
|
|
2018-11-20 |
2018-11-19 |
S
Sale
|
Howard Alvin D
VP Regulatory
Officer
|
3,375
-8.1%
3.90
USD 13,163
|
3,375
-8.1%
|
3.90
|
USD 13,163
|
|
|
2018-11-13 |
2018-11-08 |
S
Sale
|
Domzalski David
CEO
Executive Director
|
2,062
-1.3%
4.58
USD 9,444
|
2,062
-1.3%
|
4.58
|
USD 9,444
|
|
|
2018-11-13 |
2018-11-08 |
S
Sale
|
Stuart Iain
SVP R&D
Officer
|
683
-2.0%
4.58
USD 3,128
|
683
-2.0%
|
4.58
|
USD 3,128
|
|
|
2018-10-02 |
2018-10-01 |
S
Sale
|
Domzalski David
CEO
Executive Director
|
601
-0.4%
5.81
USD 3,492
|
601
-0.4%
|
5.81
|
USD 3,492
|
|
|
2018-10-02 |
2018-10-01 |
S
Sale
|
Elliott Russell P.
VP Drug Development
Officer
|
142
-1.1%
5.81
USD 825
|
142
-1.1%
|
5.81
|
USD 825
|
|
|
2018-10-02 |
2018-10-01 |
S
Sale
|
Howard Alvin D
VP Regulatory
Officer
|
234
-0.6%
5.81
USD 1,360
|
234
-0.6%
|
5.81
|
USD 1,360
|
|
|
2018-09-06 |
2018-09-04 |
S
Sale
|
Domzalski David
CEO
Executive Director
|
67
-0.0%
5.67
USD 380
|
67
-0.0%
|
5.67
|
USD 380
|
|
|
2018-08-09 |
2018-08-08 |
S
Sale
|
Domzalski David
CEO
Executive Director
|
8,238
-5.1%
5.68
USD 46,792
|
8,238
-5.1%
|
5.68
|
USD 46,792
|
|
|
2018-08-09 |
2018-08-08 |
S
Sale
|
Stuart Iain
SVP R&D
Officer
|
2,715
-7.3%
5.68
USD 15,421
|
2,715
-7.3%
|
5.68
|
USD 15,421
|
|
|
2018-07-03 |
2018-07-02 |
S
Sale
|
Domzalski David
CEO
Executive Director
|
602
-0.4%
5.10
USD 3,070
|
602
-0.4%
|
5.10
|
USD 3,070
|
|
|
2018-07-03 |
2018-07-02 |
S
Sale
|
Elliott Russell P.
VP Drug Development
Officer
|
142
-1.1%
5.10
USD 724
|
142
-1.1%
|
5.10
|
USD 724
|
|
|
2018-07-03 |
2018-07-02 |
S
Sale
|
Howard Alvin D
VP Regulatory
Officer
|
234
-0.6%
5.10
USD 1,193
|
234
-0.6%
|
5.10
|
USD 1,193
|
|
|
2018-06-04 |
2018-06-01 |
S
Sale
|
Domzalski David
CEO
Executive Director
|
67
-0.0%
5.26
USD 352
|
67
-0.0%
|
5.26
|
USD 352
|
|
|
2018-05-31 |
2018-05-13 |
S
Sale
|
Hirsch Stanley
Non-Executive Director
|
6,164
-48.6%
5.09
USD 31,369
|
6,164
-48.6%
|
5.09
|
USD 31,369
|
|
|
2018-04-04 |
2018-04-02 |
S
Sale
|
Howard Alvin D
VP Regulatory
Officer
|
234
-0.6%
5.08
USD 1,189
|
234
-0.6%
|
5.08
|
USD 1,189
|
|
|
2018-04-04 |
2018-04-02 |
S
Sale
|
Elliott Russell P.
VP Drug Development
Officer
|
142
-1.1%
5.08
USD 721
|
142
-1.1%
|
5.08
|
USD 721
|
|
|
2018-04-04 |
2018-04-02 |
S
Sale
|
Domzalski David
CEO
Executive Director
|
602
-0.4%
5.08
USD 3,058
|
602
-0.4%
|
5.08
|
USD 3,058
|
|
|
2018-03-06 |
2018-03-02 |
S
Sale
|
Elliott Russell P.
VP Drug Development
|
817
-6.0%
6.14
USD 5,016
|
817
-6.0%
|
6.14
|
USD 5,016
|
|
|
2018-03-05 |
2018-03-01 |
S
Sale
|
Domzalski David
CEO
Executive Director
|
66
-0.0%
5.95
USD 393
|
66
-0.0%
|
5.95
|
USD 393
|
|
|
2018-01-18 |
2018-01-11 |
PS
Planned sale
|
Eini Meir
|
5,000
-0.2%
6.33
USD 31,659
|
5,000
-0.2%
|
6.33
|
USD 31,659
|
|
|
2018-01-18 |
2018-01-10 |
PS
Planned sale
|
Eini Meir
|
5,000
-0.2%
6.05
USD 30,227
|
5,000
-0.2%
|
6.05
|
USD 30,227
|
|
|
2018-01-18 |
2018-01-09 |
PS
Planned sale
|
Eini Meir
|
5,000
-0.2%
6.10
USD 30,520
|
5,000
-0.2%
|
6.10
|
USD 30,520
|
|
|
2018-01-18 |
2018-01-08 |
PS
Planned sale
|
Eini Meir
|
5,000
-0.2%
6.17
USD 30,850
|
5,000
-0.2%
|
6.17
|
USD 30,850
|
|
|
2018-01-18 |
2018-01-05 |
PS
Planned sale
|
Eini Meir
|
5,000
-0.2%
6.58
USD 32,882
|
5,000
-0.2%
|
6.58
|
USD 32,882
|
|
|
2018-01-18 |
2018-01-04 |
PS
Planned sale
|
Eini Meir
|
5,000
-0.2%
6.68
USD 33,411
|
5,000
-0.2%
|
6.68
|
USD 33,411
|
|
|
2018-01-18 |
2018-01-03 |
PS
Planned sale
|
Eini Meir
|
5,000
-0.2%
6.26
USD 31,311
|
5,000
-0.2%
|
6.26
|
USD 31,311
|
|
|
2018-01-18 |
2018-01-02 |
PS
Planned sale
|
Eini Meir
|
5,000
-0.2%
6.18
USD 30,903
|
5,000
-0.2%
|
6.18
|
USD 30,903
|
|
